drugset / Trial / NCT01502137

Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis

NCT01502137

Phase 1 Completed 21 enrolled Novo Nordisk A/S
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to to compare steady-state total growth hormone (GH) exposure in haemodialysis (HD) patients with that of matched healthy subjects.

Timeline

Start
2005-06
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 50 ug/kg Subcutaneous